drugset / Trial / NCT03592693

Vitamin C, Hydrocortisone and Thiamine for Septic Shock

NCT03592693

RandomizedParallel-groupQuadruple-blindTreatment

Summary

Prior data has shown that both corticosteroids and vitamin C reduce the activation of nuclear factor ƘB (NFƘB), thereby ultimately attenuating the systemic inflammatory response to sepsis/septic shock and augmenting the responsiveness to vasopressors. Therefore, the current investigators hypothesized that the combined use of vitamin C and stress-dose hydrocortisone may improve the outcomes of patients with septic shock. The investigators intend to perform a randomized, multicenter, parallel group, double-blind, placebo-controlled trial of vitamin C plus stress-dose hydrocortisone or placebo plus placebo for a total of four days after randomization of patients fulfilling the current consensus criteria for septic shock. The primary outcome will be hospital mortality, whereas the scondary outcomes will include 60-day, 28-day mortality, time to vasopressor cessation, procalcitonin clearance and change in the Sequential Organ Failure Assessment score over the first 4 days after randomization, neurologic failure-free days, and length of stay in the intensive care unit (ICU) and the hospital. Target enrollment will be 400 patients.

Timeline

Start
2018-09-06
Primary completion
2023-01-16
Completion
2023-01-16

Drugs

EvaluationDrugModalityDoseRoute
Subject Hydrocortisone Other / unclassified 50 mg Intravenous
Subject Vitamin C Other / unclassified 1500 mg Intravenous

Indications

No indication recorded.